(Remy Peptides) For context, these results place retatrutide among the most potent pharmacologic weight-loss treatments ever studied, potentially exceeding outcomes seen with earlier GLP-1 therapies
The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance
Dosing in the Phase 3 Diabetes Trial (TRANSCEND-T2D-1) A1C reduction: -1.7% to -2.0% across doses (from baseline 7-9.5%) Weight loss at 12 mg: 16.8% (-36.6 lbs) at 40 weeks Discontinuation due to adverse events was relatively low across all doses, similar to the patterns seen in TRIUMPH-4 The diabetes population typically loses less weight on GLP-1 drugs than the obesity-only population, which is consistent with what was observed: ~17% weight loss in T2D vs
Sorli C et al
GLP-1 RAs are known to have a beneficial effect on lipid profile and blood pressure (BP)
Michael Camilleri, Mayo Clinic Working closely with healthcare providers to adjust doses, address complications, and refine dietary plans can help patients stay on track with their treatment
